Hydroxychloroquine, as shown by Sacre and colleagues, could reduce the capacity of pDCs in producing IFN-α and TNF-α upon in vitro stimulation with TLR9 and TLR7 agonists in SLE patients [31]. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.